Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients with Severe Asthma - ALIZE

Study identifier:D3250C00033

ClinicalTrials.gov identifier:NCT02814643

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients with Severe Asthma.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine

Sex

All

Actual Enrollment

103

Study type

Interventional

Age

12 Years - 21 Years

Date

Study Start Date: 01 Jul 2016
Primary Completion Date: 24 Jan 2017
Study Completion Date: 24 Jan 2017

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Supportive Care

Verification:

Verified 01 Oct 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria